Press releaseGlobe Newswire
Grace Therapeutics
GRCE · NASDAQ
$1.98+$0.10 (+5.32%)TodayMarket closed ·
Prev close $1.88
Latest news
- Press releaseGlobe Newswire
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
- News
Reported Earlier, Grace Therapeutics Prices Private Placement Of 4,761,904 Shares At $2.10 Per Share To Fund GTx-104 Manufacturing And Regulatory Work
- Press releaseGlobe Newswire
Grace Therapeutics Announces $10 Million Private Placement
- Press releaseGlobe Newswire
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
- News
Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) Estimate
- Press releaseGlobe Newswire
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
- Press releasePRNewswire
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releaseGlobe Newswire
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.
- Press releaseBusiness Wire
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
- NewsVandana Singh
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
- Press releaseGlobe Newswire
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
- Press releaseGlobe Newswire
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
- Press releaseGlobe Newswire
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
- Press releaseGlobe Newswire
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.